398 related articles for article (PubMed ID: 501288)
1. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
[TBL] [Abstract][Full Text] [Related]
2. A molecular basis of activation of the alternative pathway of human complement.
Austen KF; Fearon DT
Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
[TBL] [Abstract][Full Text] [Related]
3. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces.
Carreno MP; Labarre D; Maillet F; Jozefowicz M; Kazatchkine MD
Eur J Immunol; 1989 Nov; 19(11):2145-50. PubMed ID: 2480904
[TBL] [Abstract][Full Text] [Related]
5. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
Melamed J; Medicus RG; Arnaout MA; Colten HR
J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
7. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.
Meri S; Pangburn MK
Proc Natl Acad Sci U S A; 1990 May; 87(10):3982-6. PubMed ID: 1692629
[TBL] [Abstract][Full Text] [Related]
8. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
[TBL] [Abstract][Full Text] [Related]
9. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
[TBL] [Abstract][Full Text] [Related]
10. Phagocytosis by human monocytes of particles activating the alternative pathway of complement.
Johnson E; Eskeland T; Bertheussen K
Scand J Immunol; 1984 Jan; 19(1):31-9. PubMed ID: 6701471
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
[TBL] [Abstract][Full Text] [Related]
12. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
[TBL] [Abstract][Full Text] [Related]
13. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
14. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
15. Species specificity of recognition by the alternative pathway of complement.
Horstmann RD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Feb; 134(2):1101-4. PubMed ID: 3155536
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
[TBL] [Abstract][Full Text] [Related]
17. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
Fearon DT
Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
[TBL] [Abstract][Full Text] [Related]
18. Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.
Kings M; Nydegger UE; de Weck AL
Immunology; 1984 Jan; 51(1):123-31. PubMed ID: 6197357
[TBL] [Abstract][Full Text] [Related]
19. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
20. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
Lambré CR; Kazatchkine MD; Maillet F; Thibon M
J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
